MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
Kura Oncology, Inc (NASDAQ: KURA)*
Organization & Developments: Kura
Parents
Kura Oncology, Inc (NASDAQ: KURA)*
Children
* Engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers.
*Candidate, Tipifarnib, is a farnesyl transferase inhibitor, in both solid tumors and blood cancers.
*Develops small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers.
2016: Biotech Forum Daily Digest: When Will The Pain Stop? Endo's Implosion, Spotlight On Kura Oncology
2016: Kura Oncology (NASDAQ:KURA) - 16% discount to net cash
2018: Kura Oncology: A Winner At ASH, What To Expect In 2019_seekingalpha.com
2018: Kura Oncology: Data Continues To Propel Shares Higher_seekingalpha.com
2019: The Prognosis For Kura Oncology - Kura Oncology (NASDAQ:KURA)
2020: Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks
2020: Looking Under The Covers At Kura Oncology
2021: Kura Oncology’s Small Molecules Hint at Major Therapeutic Breakthroughs
2022: Circling Back On Kura Oncology_ seekingalpha.com
2022: Kura Oncology (KURA) Investor Presentation - Slideshow_seekingalpha.com
2023: Kura Oncology: Riding The Menin Hype Wave In AML Therapy_seekingalpha.com
2024: Kura Crashes 37% After $1.53 Billion Deal Slams The Door On A Takeover
2024: Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)seekingalpha.com
2024: Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Kura Oncology: A Contender In The Field Of Precision Medicine
2024: Kura Oncology: The Long Holding Pattern Is Risky
2024: Kura Oncology: Ziftomenib's Path To AML Market Widens
2024: Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug ahead of push to FDA
2025: Kura Oncology rises after new early-stage trial data for leukemia therapy
2025: Kura Oncology wins FDA nod for leukemia drug (KURA:NASDAQ)
2025: Kura Oncology: Sentiment Is Too Negative
2025: Kura Oncology: The Market Sees A Tough Road Ahead, And I Think There's An Opportunity
2025: Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well
Jumps
*Key People: Kura
Finance & Acquisitions: Kura